[go: up one dir, main page]

AR055192A1 - 2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos - Google Patents

2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos

Info

Publication number
AR055192A1
AR055192A1 ARP050102012A ARP050102012A AR055192A1 AR 055192 A1 AR055192 A1 AR 055192A1 AR P050102012 A ARP050102012 A AR P050102012A AR P050102012 A ARP050102012 A AR P050102012A AR 055192 A1 AR055192 A1 AR 055192A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
heteroaryl
cycloalkyl
nr18r19
Prior art date
Application number
ARP050102012A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR055192A1 publication Critical patent/AR055192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Estos compuestos resultan utiles para tratar enfermedades alérgicas e inflamatorias, enfermedades del S.N.C. y diabetes. Reivindicacion 1: Un compuesto representado por la formula estructural (1) o una sal o solvato del mismo aceptable para uso farmacéutico, donde el anillo A es como los compuestos de formulas (2); R es H o alquilo, X es O o S; R1 es H, alquilo, cicloalquilo, cicloalquilC1-4alquilo-, - CH2F, -CHF2, -CF3, -C(O)alquilo o -C(O)NR18R19; R3 y R4 se seleccionan en forma independiente del grupo integrado por H, alquilo, hidroxialquilo y -C(O)Oalquilo; R5 y R6 se seleccionan en forma independiente del grupo integrado por H, alquilo, hidroxialquilo, alcoxialquilo, mercaptoalquilo, -CH2F, -CHF2, -CF3, -C(O)OH, - C(O)Oalquilo y -C(O)NR43R44; t es 1 o 2; R7 es H es H, alquilo, alquenilo, hidroxialquilo, cicloalquilo, alcoxialquilo, aminoalquilo, (R17-fenil)alquilo o -CH2-C(O)-O-alquilo; R8 es H, alquilo, alquenilo, alcoxi, alcoxialquilo, hidroxialquilo, dihidroxialquilo, alquil-NR18R19, cianoalquilo, haloalquilo, R23-heteroarilo, R23-heteroarilalquilo, R36-heterocicloalquilo, (R36-heterocicloalquiI) alquilo, R17-fenilo, (R17-fenil)alquilo, R17-naftilo, (R17-naftil)alquilo, R17-benciloxi, -alquil- C(O)-NR18R19, -alquil-C(O)-N(R30)-(R23- heteroarilo), -alquil-C(O)-(R17-fenilo), -alquiI-C(O)-(R36-heterocicloalquilo); -alquil-N(R30)-C(O)Oalquilo, -alquil-N(R30)-C(O)-NR18R19, -alquil- N(R30)-C(O)alquilo, -alquil-N(R30)-C(O)-(fluoroalquilo), -alquil- N(R30)-C(O)-(R39-cicloalquilo), -alquil-N(R30)-C(O)-(R17-fenilo), -alquil-N(R30)- C(O)-(R23-heteroarilo), -alquil-N(R30)-C(O)-alquilen-(R23-heteroarilo), -aIquil-NH-SO2-NR18R19, -alquil-N(R30)-(R17-fenilo), -alquil- N(R30)-(R23-heteroarilo), -alquil-O- (R17-fenilo), -alquil-O-(R23-heteroarilo), -alquil-N(R30)-SO2-alquilo, alquiltioalquilo-, alquil-SO2-alquilo-, (R35-fenilalquil)-S-alquilo-, (hidroxialquil)-S-alquilo-, (alcoxialquil)-S-alquilo-, -alquil-CO2-alquilo, R45-hidroxialquilo, dihidroxialquilo sustituido con R17-benciloxi, dihidroxialquilo sustituido con R17-fenilo, alcoxialquilo sustituido con R17-fenilo, (R17-fenil)alquilo sustituido con -CO2alquilo, (R17-fenil)alquilo sustituido con -C(O)N(R30)2, alquilo sustituido con (R23-heteroarilo) y -C(O)NR37R38, haloalquilo sustituido con CO2alquiIo, R12-cicloalquilo, (R12-cicloalquil)alquilo, el grupo de formulas (3) o R7 y R8 y el N al cual están unidos forman un sistema anular seleccionado del grupo integrado por las formulas (4) donde el resto (5) comprende un grupo heteroarilo de 5 o 6 miembros sustituido con R35 fusionado al anillo piperidinilo o pirrolidinilo; p es 0 o 1; q es 0 o 1; la línea de puntos representa un doble enlace opcional; R9 es H, halo, alquilo, cicloalquilo, -CH2F, -CHF2 o CF3, R10, R11 y R13 se seleccionan en forma independiente del grupo integrado por H y halo; R12 es 1-3 sustituyentes seleccionados en forma independiente del grupo integrado por H, alquilo, hidroxi, alcoxi, hidroxialquilo, alcoxialquilo, -C(O) Oalquilo, -(CH2)n-N(R30)-C(O)-cicloalquilo, -(CH2)n-N(R30)-C(O)alquilo, -(CH2)n-N(R30)-C(O)Oalquilo, -(CH2)n-N(R30)-(R23-heteroarilo), -(CH2)n-N(R30)-C(O)-NR18R19, -(CH2)n-C(O)-NR18R19, R17-fenilo, R35- heteroarilalquilo, R35-heteroariloxi, -C(O)-heterocicloalquilo, -O-C(O)- heterocicloalquilo, -O-C(O)-NR18R19, -NH-SO2-alquilo, -NH-C(=NH)NH2 y el resto de formula (6), o dos sustituyentes R12 sobre el mismo carbono forman =O, =NOR30 o =CH2; R14 es 1 o 2 sustituyentes seleccionados en forma independiente del grupo integrado por H, OH, halo, alquilo, alcoxi, hidroxialquilo, alcoxialquilo, -CF3, CN, R17-fenilo, (R17-fenil)alquilo, -NR18R19, alquil-NR18R19, -(CH2)n-C(O)OH, -(CH2)n-C(O) Oalquilo, - (CH2)n-C(O)aIquilo, -(CH2)n-C(O)(R35-feniIo), -(CH2)n-C(O)(R23-heteroarilo), -(CH2)n-C(O)NR18R19, -(CH2)n-C(O)N(R30)-(CH2) n-(R23-heteroarilo), -(CH2)n-N(R30)-C(O)alquilo, -(CH2)n-N(R30)-C(O)-(fluoroalquiIo), -(CH2)n-N(R30)-C(O)-(cicloalquilo), - (CH2)n-N(R30)- C(O)(R35-fenilo), -(CH2)n,-N(R30)-C(O)(R23-heteroarilo), -(CH2)n-N(R30)C(O)NR18R19, -(CH2)n-N(R30)-C(O)OaIquilo, -(CH2)n-N(R30) cicloalquilo, -(CH2)n-N(R30)(R17-fenilo), -(CH2)n-N(R30)(R23-heteroarilo), -(CH2)n-N(R18)SO2alquilo, -(CH2)n- N(R20)SO2-(R17-fenilo), -(CH2)n-N(R30)SO2-CF3, -CH2S(O)0-2(R35-fenilo), -(CH2)n-OC(O)N(R30)alquilo, R23-heteroarilo, (R23- heteroaril)alquilo, (R23-heteroaril)oxi, (R23-heteroaril)amino, -CH(OH)-(R17-fenilo), -CH(OH)-(R23-heteroarilo), -C(=NOR30)- (R17-fenilo), -C(=NOR30)-(R23-heteroarilo), morfolinilo, tiomorfolinilo, los restos de formulas (7); w es 0 o 1; o dos sustituyentes R14 y el C al que ambos están unidos forman -C(=NOR30)- o -C(O)-; cada n es en forma independiente 0, 1, 2 o 3; R15 es H, alquilo, cicloalquilo, (cicloalquil)alquilo, hidroxialquilo, alcoxialquilo, haloalquilo, -C(O) Oalquilo, C(O)O(R30-cicloaIquilo), -aIquil-C(O)Oalquilo, -C(O)O-alquilen-(R35-fenilo), R17-fenilo, (R17-fenil)alquilo, -CH-(R17-fenilo)2, R23- heteroarilo, -(CH2)nC(O)NR18R19, -SO2-alquilo, -SO2-cicloalquilo, -SO2-CF3, -SO2-(R35-fenilo), -SO2-NR18R19, -C(O)alquilo, - C(O)-(fluoroalquilo), -C(O)-C(CH3)(CF3)2, -C(O)-(R17-fenilo), -C(O)-(R23-heteroarilo), -C(O)-hidroxialquilo, -C(O)- alcoxialquilo, -C(O)-(R39- cicloalquilo), -C(O)-alquilen-(R17-fenilo), -C(O)-alquilen-(23-heteroarilo), -C(O)-alquilen-S-C(O)alquilo, -C(=S)-(R17-fenilo), hidroxialquilo sustituido con R17-fenilo, hidroxialquilo sustituido con R23-heteroarilo, alcoxialquilo sustituido con R17-fenilo, alcoxialquilo sustituido con R23- heteroarilo, los restos de formulas (8), donde z es 0, 1 o2; R16 es 1 a 4 sustituyentes seleccionados en forma independiente del grupo integrado por H, alquilo, R17-fenilo, (R17-fenil)alquilo, (R23-heteroaril)alquilo, hidroxialquilo, alcoxialquilo y -C(O)Oalquilo, o dos grupos R16 y el carbono al que ambos están unidos forman -C(O)-; R17 es 1 a 3 sustituyentes seleccionados en forma independiente del grupo integrado por H, halo, alquilo, cicloalquilo, -OH, hidroxialquilo, alcoxi, alcoxialquilo, -CN, -CF3, -OCF3, -OCHF2, -OCH2F, -C(O)OH, -C(O)Oalquilo, -C(O)O-(R35- fenilo), -C(O)alquilo, -C(O)-(R35-fenilo), -SOalquilo, -SO2alquilo, -SO2-CF3, alquiltio, -NR43R44, - alquil-NR43R44, R35-fenilo, R35-fenoxi, R35- heteroarilo, R35-heteroariloxi, R36-heterocicloalquilo, -C(O)-(R36-heterocicloalquilo), hidroxialquil-NH-, -C(O)N(R30)2, -N(R43)-(R35- cicloalquilo) y -C(=NOR30); o dos sustituyentes R17 sobre átomos de carbono adyacentes conjuntamente forman -O-CH2-O-, -O(CH2)2-O-, -(CH2)2-O- o -O-CH2-O-CH2-; R18 y R19 se seleccionan en forma independiente del grupo integrado por H, alquilo, hidroxialquilo, alcoxialquilo, haloalquilo, R17-fenilo, (R17- fenil)alquilo, naftilo y cicloalquilo; R20 es H, alquilo o cicloalquilo; R22 es 1 a 4 sustituyentes seleccionados en forma independiente del grupo integrado por H, alquilo, hidroxi, alcoxi, halo, -CF3, -NH2 y R35-feniIo; R23 es 1 a 4 sustituyentes seleccionados en forma independiente del grupo integrado por H, alquilo, hidroxi, alcoxi, halo, -CF3, -NR18R19, -CN, -C(O)Oalquilo, -SO2-alquilo, -NHSO2- alquilo, R35-fenilo, R35-heteroarilo, morfolinilo y -(CH2)n-C(O)-N(R30)2; R24 es H, OH o alcoxi; o cuando el doble enlace opcional está presente, R24 y el átomo de carbono adyacente forman el doble enlace; R25 es H o R35-fenilo; R27 es 1 a 3 sustituyentes seleccionados en forma independiente del grupo integrado por H, halo, OH, alquilo, alcoxi, hidroxialquilo, alcoxialquilo, haloalquilo, -CN, -C(O)OH, -C(O)Oalquilo, - C(O)N(R30)(R18), -C(O)-(R36-heterocicloalquilo), R17-fenilo, (R17-fenil)-alquilo, R23-heteroarilo, (R23-heteroaril)alquilo, (R23-heteroaril)oxi, (R23-heteroaril)amino, NR18R19, NR18R19-aIquilo, -(CH2)n-N(R30)-C(O)alquilo, -(CH2)n-N(R30)-C(O)-(fluoroalquilo), -(CH2)n-N(R30)-C(O) alcoxialquilo, -(CH2)n-N(R30)-C(O)(cicloalquilo), -(CH2)n-N(R30)-(R23-heteroarilo), -(CH2)n-N(R30)-C(O)-(R23-heteroarilo), -(CH2)n-N(R30)- C(O)O-alquilo, -(CH2)nN(R30)-C(O)O-(CF3-alquilo),-(CH2)n-N(R30)-C(O)O-(R39-cicloalquilo), -(CH2)n-N(R30)-C(O)O-alquilen-cicloalquilo, -(CH2)n-N(R30)-C(O)-N(R30)(R20), -(CH2)n-N(R30)-SO2alquilo, -(CH2)n-N(R30)-SO2CF3, (CH2)n-N(R30)-SO2-N(R30)2 y el resto de formula (9); o dos grupos R27 y el carbono al cual ambos están unidos forman -C(NOR30)- o -C(O)-; R28 es H, alquilo, R35-bencilo o -alquil-C(O)O- alquilo; R29 es alquilo, haloalquilo, -C(O)Oalquilo, -C(O)alquilo, -C(O)CF3, -C(O)-(R12- cicloalquilo), -C(O)-(R17-fenilo), -C(O)-(R23- heteroarilo), -C(O)-(R36-heterocicloalquilo), -SO2-alquilo, -SO2(R35-fenilo), -C(O)NR18R19, R35-fenilo, (R35-fenil)alquilo o R23-heteroarilo; R30 se selecciona en forma independiente del grupo integrado por H, alquilo, R35-bencilo y R35-fenilo; R31 es H, alquilo, R35-bencilo o fenoxialquilo; R33 es H, OH o alcoxi; R34 es H, alquilo, hidroxialquilo, alcoxialquilo o -C(O)Oalquilo; R35 es 1 a 3 sustituyentes seleccionados en forma independiente del grupo integrado por H, halo, alquilo, OH, -CF3, alcoxi, -CO2alquilo y -N(R43)(R44); R36 es 1 o 2 sustituyentes seleccionados en forma independiente del grupo integrado por H, alquilo, R17-fenilo, -OH, hidroxialquilo, alcoxialquilo, -C(O)Oalquilo y - NR18R19 o dos grupos R36 y el carbono al cual ambos están unidos forman -C(=NOR30)- o -C(O)-; R37 y R38 y se seleccionan en forma independiente del grupo integrado por H y alquilo, o R37 y R38 juntos son -(CH2)3- o -(CH24)-, y junto con el nitrogeno al cual están unidos, forman un anillo; R39 es H, OH, alquilo, alcoxi o CF3; R40 es -OR30 o -NHC(O)alquilo; R41 es H o -SO2alquilo; R42 es -(CH2)n-(R35-fenilo), -(CH2)n-(R23-heteroarilo), -C(O)Oalquilo o -C(O)alquilo; R43 y R44 se seleccionan en forma independiente del grupo integrado por H y alquilo; y R45 es 1 o 2 sustituyentes seleccionados en forma independiente del grupo integrado por halo, aIcoxialquilo, -CO2alquilo, R17-fenilo, R23- heteroarilo y cicloalquilo.
ARP050102012A 2004-05-18 2005-05-17 2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos AR055192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57226604P 2004-05-18 2004-05-18

Publications (1)

Publication Number Publication Date
AR055192A1 true AR055192A1 (es) 2007-08-08

Family

ID=35106691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102012A AR055192A1 (es) 2004-05-18 2005-05-17 2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos

Country Status (20)

Country Link
US (1) US7511062B2 (es)
EP (1) EP1758883B1 (es)
JP (1) JP4584990B2 (es)
KR (1) KR100907354B1 (es)
CN (1) CN1984901B (es)
AR (1) AR055192A1 (es)
AT (1) ATE531705T1 (es)
AU (1) AU2005247906B2 (es)
BR (1) BRPI0511295A (es)
CA (1) CA2565599C (es)
EC (1) ECSP067013A (es)
IL (1) IL179280A (es)
MX (1) MXPA06013414A (es)
NO (1) NO20065830L (es)
NZ (1) NZ551017A (es)
PE (1) PE20060241A1 (es)
RU (1) RU2417993C9 (es)
TW (1) TWI286475B (es)
WO (1) WO2005116009A1 (es)
ZA (1) ZA200609277B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8682279B2 (en) 2004-05-07 2014-03-25 Interdigital Technology Corporation Supporting emergency calls on a wireless local area network
KR101122359B1 (ko) 2004-05-07 2012-03-23 인터디지탈 테크날러지 코포레이션 무선 근거리 통신망의 긴급 호 지원
US8145182B2 (en) * 2004-05-07 2012-03-27 Interdigital Technology Corporation Supporting emergency calls on a wireless local area network
EP1879620A2 (en) * 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
CA2634743C (en) * 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
PL1997813T3 (pl) * 2006-03-10 2010-10-29 Nissan Chemical Ind Ltd Podstawiony związek izoksazolinowy i środek zwalczający szkodniki
BRPI0711358A2 (pt) * 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
EP2038279A2 (en) * 2006-06-06 2009-03-25 Avigen, Inc. Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
WO2008006050A2 (en) * 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
CA2657902A1 (en) * 2006-07-11 2008-01-17 Schering Corporation Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
WO2008021271A1 (en) * 2006-08-14 2008-02-21 Schering Corporation Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- [ ( 2, 4 -difluorophenyl) -methyl] - 2 - [ 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline] - 4 - oxazolecarboxamide
EP2385050A1 (en) * 2006-08-14 2011-11-09 Schering Corporation A process for preparing a substituted oxazole
CN101534822A (zh) * 2006-09-15 2009-09-16 先灵公司 治疗疼痛、糖尿病和脂质代谢紊乱
EP2061791A1 (en) 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
MX2009002922A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
JP2008260691A (ja) * 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
JP4986927B2 (ja) * 2007-05-14 2012-07-25 大塚製薬株式会社 医薬
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
EP2178867A1 (en) * 2007-07-10 2010-04-28 Schering Corporation Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
US20110003780A1 (en) * 2007-07-10 2011-01-06 Schering Corporation Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
GB2451629A (en) * 2007-08-06 2009-02-11 Univ Sheffield 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones
EP2280766A1 (en) 2007-12-11 2011-02-09 CytoPathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
EP2098526B1 (en) * 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
JP5476895B2 (ja) 2008-12-17 2014-04-23 セントラル硝子株式会社 ヒドロキシル基置換生成物の製造方法
WO2010080864A1 (en) * 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
US8796297B2 (en) 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2475659B1 (en) * 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
JP5709101B2 (ja) * 2010-09-01 2015-04-30 東レ・ファインケミカル株式会社 ヒドロキシプロリン誘導体の製造法
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
CN102408433B (zh) * 2011-10-20 2014-04-09 天津药物研究院 含嘧啶的肟类化合物、其制备方法和用途
US8530461B2 (en) * 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
JP6130828B2 (ja) 2012-04-24 2017-05-17 中外製薬株式会社 キナゾリンジオン誘導体
WO2013161851A1 (ja) * 2012-04-24 2013-10-31 中外製薬株式会社 ベンズアミド誘導体
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
MX364895B (es) * 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
AU2014338070A1 (en) 2013-10-23 2016-05-05 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CN105085429B (zh) * 2014-04-25 2019-12-10 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015253232B2 (en) 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
GB201415569D0 (en) * 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
JP2018016544A (ja) * 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
CN104829492A (zh) * 2015-05-06 2015-08-12 河北工业大学 一种反式N-Boc-1,3-环丁二胺的制备方法
CN106279138B (zh) * 2015-12-29 2019-03-01 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
KR20200104873A (ko) 2017-12-06 2020-09-04 린 바이오사이언스, 피티와이 엘티디. 튜불린 억제제
AU2019215799B2 (en) * 2018-02-01 2022-04-14 The University Of Sydney Anti-cancer compounds
KR102682705B1 (ko) * 2018-07-04 2024-07-05 고려대학교 세종산학협력단 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물
JP7458987B2 (ja) * 2018-09-13 2024-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN116963773A (zh) 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
CA3243098A1 (en) * 2022-01-28 2023-08-03 BioAge Labs, Inc. NLRP3 Inflammasome N-Oxide Inhibitors
US12509459B2 (en) 2024-03-26 2025-12-30 BioAge Labs, Inc. Inhibitors of NLRP3 inflammasome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2252501A1 (en) * 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
EP0946541B1 (en) * 1996-11-06 2003-07-30 Darwin Discovery Limited Quinolines and their therapeutic use
WO1999032450A1 (en) * 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
EP1165542B1 (en) * 1999-03-29 2003-08-20 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
ATE542805T1 (de) * 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
WO2002076957A1 (en) * 2001-03-23 2002-10-03 Nippon Chemiphar Co.,Ltd. Activator for peroxisome proliferator-activated receptor
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
CA2657902A1 (en) * 2006-07-11 2008-01-17 Schering Corporation Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound

Also Published As

Publication number Publication date
CA2565599A1 (en) 2005-12-08
BRPI0511295A (pt) 2007-12-04
EP1758883B1 (en) 2011-11-02
JP2007537300A (ja) 2007-12-20
WO2005116009A1 (en) 2005-12-08
NO20065830L (no) 2007-02-16
WO2005116009B1 (en) 2006-01-26
CA2565599C (en) 2012-07-31
TW200602056A (en) 2006-01-16
ZA200609277B (en) 2008-06-25
IL179280A (en) 2011-07-31
RU2006144709A (ru) 2008-06-27
AU2005247906A1 (en) 2005-12-08
RU2417993C9 (ru) 2011-10-10
CN1984901A (zh) 2007-06-20
RU2417993C2 (ru) 2011-05-10
KR100907354B1 (ko) 2009-07-10
MXPA06013414A (es) 2007-01-23
AU2005247906B2 (en) 2011-08-25
CN1984901B (zh) 2011-02-09
ATE531705T1 (de) 2011-11-15
TWI286475B (en) 2007-09-11
JP4584990B2 (ja) 2010-11-24
US20060106062A1 (en) 2006-05-18
ECSP067013A (es) 2006-12-29
PE20060241A1 (es) 2006-04-01
US7511062B2 (en) 2009-03-31
KR20070013306A (ko) 2007-01-30
NZ551017A (en) 2010-11-26
EP1758883A1 (en) 2007-03-07
IL179280A0 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
AR055192A1 (es) 2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR047050A1 (es) Derivados de 1,3 diazol como inhibidores de aspartilproteasa. composiciones farmacéuticas
AR035825A1 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas y sus sales como ligandos del receptor de cxc-quimiocina, composiciones farmaceuticas y el uso de las mismas para la fabricacion de un medicamento
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
AR054618A1 (es) Compuestos de azetidina y su uso como inhibidores de proteasas
AR049263A1 (es) Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR046791A1 (es) Tiadiazoles como ligandos del receptor cxc y cc-quimioquina; composiciones farmaceuticas que los contienen como principio activo y su empleo en la preparacion de medicamentos.
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
AR051469A1 (es) Derivados de indol tetraciclicos como agentes antiviricos
AR063800A1 (es) Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR040405A1 (es) Derivados de bencimidazol utiles como antagonistas de histamina h3
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
AR012340A1 (es) 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen
AR040406A1 (es) Antagonistas de histamina h3 de benzimidazolona
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR062361A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos
FR2673427B1 (fr) Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal